Movement disorders in neuroleptic-naïve patients with schizophrenia spectrum disorders by unknown
Ayehu et al. BMC Psychiatry 2014, 14:280
http://www.biomedcentral.com/1471-244X/14/280RESEARCH ARTICLE Open AccessMovement disorders in neuroleptic-naïve patients
with schizophrenia spectrum disorders
Moges Ayehu1, Teshome Shibre2,3, Barkot Milkias2 and Abebaw Fekadu2,4*Abstract
Background: Spontaneous Movements Disorders (SMDs) or dyskinetic movements are often seen in patients with
schizophrenia and other psychotic disorders, and are widely considered to be adverse consequences of the use of
antipsychotic medications. Nevertheless, SMDs are also observed in the pre-neuroleptic ear and among patients
who were never exposed to antipsychotic medications. The aim of this study was to determine the extent of SMDs
among antipsychotic-naïve patients in a low income setting, and to evaluate contextually relevant risk factors.
Methods: The study was a cross-sectional facility-based survey conducted at a specialist psychiatric hospital in Addis
Ababa, Ethiopia. Consecutive consenting treatment-naïve patients with a diagnosis of schizophrenia, schizoaffective
disorder and schizophreniform disorder contacting services for the first time were assessed using the Simpson-Angus
Rating Scale (SAS) and the Abnormal Involuntary Movement Scale (AIMS) to evaluate the presence of SMDS. Scale for
the Assessment of Negative Symptoms (SANS) and Scale for the Assessment of Positive Symptoms (SAPS) were
administered to evaluate negative and positive symptom profiles respectively. Body mass index (BMI) was used as a
proxy measure for nutritional status.
Result: Sixty-four patients, 67.2% male (n = 43), with first contact psychosis who met the DSM-IV-TR criteria for
schizophrenia (n = 47), schizophreniform disorder (n = 5), and schizoaffective disorder (n = 12) were assessed over a
two month study period. Seven patients (10.9%) had SMDs. BMI (OR = 0.6, 95% CI = 0.40, 0.89; p = 0.011) and
increasing age (OR = 1.10; 95% CI = 1.02, 1.20; p = 0.017) were associated with SMD.
Conclusions: This finding supports previous suggestions that abnormal involuntary movements in schizophrenia
and other psychotic disorders may be related to the pathophysiology of psychotic disorders and therefore cannot
be attributed entirely to the adverse effects of neuroleptic medication.
Keywords: Parkinsonism, Dyskinesia, Spontaneous movement disorders, Dyskinetic movements, Antipsychotics,
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Different neurological motor abnormalities, especially dys-
kinesia and parkinsonism, have been reported in patients
with schizophrenia [1-5]. With the introduction of anti-
psychotic medications and their numerous neurological
adverse effects, these neurological abnormalities were
generally presumed to be consequences of treatment
with these newly introduced medications [6]. However,
a wide range of neurological motor disturbances has* Correspondence: Abe.wassie@kcl.ac.uk
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unless otherwise stated.been reported in patients with schizophrenia who have
never been treated with antipsychotic drugs, pre-dating
the antipsychotic-era [7-10]. For example, research in the
past two decades has identified spontaneous dyskinesia in
a proportion of drug-naïve patients with schizophrenia
[11-14]. Spontaneous movement disorders (SMD), includ-
ing tardive dyskinesia-like syndrome, were reported in 4%
to 11% of patients with no prior treatment history with
antipsychotic medications [10-17]. In a recent review of
13 studies, the median rate of spontaneous dyskinesia was
9%, with spontaneous parkinsonism being the commoner
abnormality [5]. Muscle rigidity and bradykinesia, often
referred to together as akinetic type signs, are reported to
be the most common parkinsonian signs in drug-naïveLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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such as tremor, glabellar tap, and salivation [12,18-22].
Non-akinetic parkinsonism becomes more severe follow-
ing treatment with antipsychotics than the akinetic type
and it has been suggested that it may be primarily a drug-
induced phenomenon [21,22]. The most commonly re-
ported dyskinetic symptoms are involuntary orofacial
movements [8,14]. SMDs have also been reported in rela-
tives of those with schizophrenia and dyskinesia, as well
as in subjects with schizophrenia spectrum personality
conditions, especially in schyzotypal personality [17,23,24].
The main factors reported to have significant associ-
ation with SMD were patients’ age, psychopathology,
pre-morbid functioning, educational achievement, and
IQ [12,14,19-22,25-31]. In addition, there is preliminary
evidence that pre-existing abnormal movements increase
the risk of subsequent extrapyramidal side effects.
Based on the above observations, it has been proposed
that idiopathic extrapyramidal disturbances may be in-
trinsic to the pathophysiology of schizophrenia and that
antipsychotic medications may act by modifying the ex-
pression of disease-based motor dysfunctions [32-34],
perhaps through specific alterations in subcortical dopa-
mine neuronal activity due to basal ganglia dysregulation
and dysfunction in cortical-basal, ganglia-cortical cir-
cuitry [18]. It is unclear how much ‘neuroleptic-induced’
motor disturbance should actually be attributed to the
natural history of psychosis, aging, or other nondrug
causes. Identifying this may be relevant to reducing
negative attitude towards the side effects of antipsychotic
medications and enhancing our understanding of the
pathophysiology of psychosis. At present, nearly all pa-
tients with psychotic disorders in high income countries
are exposed to antipsychotic medications [25]. In low in-
come countries like Ethiopia, up to 90% of patients may
not be exposed to antipsychotic medications [35,36],
providing an opportunity to explore the prevalence and
determinants of SMD among patients not exposed to
antipsychotic treatments.
There are no published data from Ethiopia reporting
on the prevalence of extrapyramidal symptoms or side
effects; however, the incidence and prevalence of these
symptoms are likely to be comparable to what has been
reported in the broader literature. There are at least
three outstanding issues that need addressing, which
may be potentially relevant to our knowledge of extra-
pyramidal symptoms: 1) The contribution of antipsy-
chotics above and beyond the natural risk of movement
disorders is unclear; 2) the prevalence of movement dis-
orders in treatment-naïve patients is not well docu-
mented in low income settings; 3) it has not yet been
established whether there are unique risk factors more
relevant for low income settings, such as malnutrition,
infection and trauma.Objectives
The primary objective of the study was to assess the ex-
tent of SMDs among antipsychotic-naïve patients with
schizophrenia spectrum disorders (schizophrenia, schi-
zoaffective and schizophreniform disorder) attending
the outpatient department of a psychiatric hospital in
Ethiopia. We additionally aimed to determine the asso-
ciation of socio-demographic and clinical factors with
SMDs, including the occurrence of potential risk factors
that may be contextually relevant, such as nutritional
status.
Methods
Study design and setting
The study was a facility-based cross-sectional survey
conducted at a psychiatric hospital located in the capital
city, Addis Ababa. The hospital is the oldest and largest
public psychiatric hospital in Ethiopia. Patients nation-
wide come to the hospital to receive treatment for severe
mental disorders. The hospital service is organized under
specialist programs or specialist case teams and each case
team is expected to have expert knowledge about the
disorders it treats. Patients with psychotic disorders are
treated by psychoses case teams. These case teams man-
age all individuals with psychosis referred or seen by the
hospital.
Participants
Participants of this study were patients aged between 18
and 60 years with a clinical diagnosis of schizophrenia,
schizoaffective and schizophreniform disorders with no
previous antipsychotic treatment or current treatment
with medications that could induce extrapyramidal
symptoms such as metoclopramide or other antiemetics.
Other drugs that may induce extrapyramidal symptoms
such as amoxapine and buspirone were not considered be-
cause they were not available in the Ethiopia market. Per-
sons above the age of 60 were excluded because of the
concern that older age may increase the risk of movement
disorders as well as the potential for somatic and neuro-
logical diseases. Additionally, patients with catatonia were
excluded as catatonia may be confused with other move-
ment abnormalities.
Assessment
Successive patients were screened from the triage unit
by a final-year psychiatry resident and consenting patients
fulfilling inclusion criteria were offered a detailed assess-
ment. Assessments consisted of an evaluation of basic
socio-demographic characteristics, diagnosis, symptom se-
verity, physical health status and occurrence of SMDs.
Nutritional status, history of serious head injury and birth
trauma were evaluated as contextually relevant risk fac-
tors. All assessments were made by the same final-year
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zoaffective disorder or schizophreniform disorder was
confirmed using a diagnostic check list from the Text
Revision of the Diagnostic and Statistical Manual of
Mental Disorders [37]. The presence of extrapyramidal
symptoms was evaluated using Simpson-Angus Scale
(SAS) [38] and Abnormal Involuntary Movement Scale
(AIMS) [39]. The SAS is a 10-item scale and has been
shown to have good sensitivity [38]. The extrapyramidal
symptoms assessed by the SAS are rigidity, hypersaliva-
tion, glabellar reflex, and tremor. On most items, sever-
ity is scored from 0 (none) to 4 (severe). A score of 1
usually indicates the presence of the extrapyramidal
symptoms in a mild form. The commonly used thresh-
old value to diagnose parkinsonism is 0.3 or more,
which is used as a cut-off score to confirm occurrence
of parkinsonism in the current report. The AIMS is
commonly used to evaluate dyskinetic symptoms. The
12 questions of the AIMS cover anatomical locations of
the dyskinetic movements (face, extremities, and trunk),
global severity of the dyskinesia, global judgment of in-
capacitation and awareness of abnormality. The AIMS
is administered through a clinician interview and phys-
ical examination. Scores on AIMS range from 0 (absent)
to 5 (severe). Conventionally, dyskinesia is present, ac-
cording to the AIMS scale, when there are mild move-
ments in at least two areas or moderate movements in
at least one area [40].
Patient symptoms profile and severity were assessed
using the Scale for the Assessment of Positive Symptoms
(SAPS) and Scale for the Assessment of Negative Symp-
toms (SANS) [41,42]. Both scales were designed to provide
a detailed assessment of positive and negative symptoms
of schizophrenia and can be used separately or in tandem.
The domains assessed in the SAPS include hallucinations,
delusions, bizarre behavior, and thought disorders, while
the domains assessed in the SANS include affective flat-
tening, poverty of speech, apathy, anhedonia, and inatten-
tiveness. Nutritional status of participants was measured
by the Qutelet’s body mass index (BMI), a measure often
used to define nutritional status in adults. It is estimated
as weight in kilograms divided by height in metres
squared. The BMI is easy to measure and closely relates to
individuals’ food consumption levels. The BMIs of the par-
ticipants were categorized according to the recommenda-
tions of the WHO Expert Committee for chronic energy
deficiency [43]. According to this WHO classification, par-
ticipants with BMI values of less than 16 were considered
to have severe energy deficiency; those with scores of
16–16.9 to have moderate deficiency; and those with
scores of 17–18.4 to have mild deficiency. Those with
BMI values of 18.5-24.9 were considered to be normal.
Mid-arm circumference was also assessed as an additional
measure of nutritional status. Finally, use of substances ofpotential abuse (alcohol, khat, cigarettes and cannabis)
was assessed. The assessment considered initially whether
the participant had lifetime or current use of these sub-
stances and those reporting use in the past year were
questioned in more detail about the frequency and quan-
tity of the substances used.
Data management
Data were collected by a final-year psychiatry resident
who received a half-day of training in addition to the
extensive residency training he had received. Data were
entered into the Statistical Package for Social Sciences,
Version 15 for Windows for analysis. The focus of the
analyses was on simple descriptive outputs (frequencies,
percentages, means and standard deviations). Normality
of continuous variables was checked visually using histo-
gram and tested using Kolmogorov-smirnov test. For nor-
mally distributed data, equality of variance was checked
using Leven’s test before applying T-test. The few analyses
for comparison and associations used the Independent
Sample T-test and logistic regression analysis. Because of
the small number of cases, only bivariate associations were
explored.
Ethical considerations
The proposal was approved by the Scientific Committee
of the Department of Psychiatry, School of Medicine,
College of Health Sciences, Addis Ababa University and
the Ethics Committee of Amanuel Specialised Mental
Hospital. Interviews were conducted in private after
obtaining informed consent. Analysis was conducted
on anonymised data. Any new clinically relevant informa-
tion generated in the research interview was passed on to
the clinical team for the benefit of the participant.
Result
Socio-demographic and clinical characteristics of the
participants
Sixty-four patients, mostly men (n = 43/64; 67.2%), with
first contact psychosis were assessed over a 3 month
period (April 01- June 30, 2013) prior to exposure to anti-
psychotic or other psychotropic medications. The age of
participants was between 18 and 60 years and the mean
(SD) age was 29.2 (9.5). Most participants were single
(44/64; 68.8%) and had a diagnosis of schizophrenia (n =
47; 73.4%). The duration of illness prior to presentation
(duration of untreated psychosis) was between 1 month
and 156 months, with a median (IQR) of 24 months
(12, 57 months). Details are provided in Table 1.
Spontaneous movement disorders or dyskinetic
movements
Based on standard cut-off points used to make a diagno-
sis of movement disorders, seven cases (10.9%) were
Table 1 Distribution of patients by socio-demographic
characteristics
Characteristics Number Percent
Sex Male 43 67.2
Female 21 32.8
Age (in years) 18-24 28 43.8
25-34 13 20.3
35 and above 23 35.9
Educational status Not able to read and write 10 15.6
Basic writing and reading
upto grade 6
21 32.8
Above grade 6 33 51.5
Religion Orthodox Christian 37 57.8
Muslims 22 34.4
Others 5 7.8
Marital status Married 11 27.3
Single 44 68.8
Divorced or separated 9 14.1




Occupation Unemployed 27 42.2
Self-employed 14 21.9
Farmer 14 21.9
Student/house wife 9 14.1
Living
arrangement
Living with parent or sibling 52 81.3
Living alone or with own
family
12 18.7
Diagnosis Schizophrenia 47 73.4
Schizophreniform disorder 5 7.8
Schizoaffective disorder 12 18.8
Duration of illness ≤1 year 23 35.9
1-2 years 11 17.2
2-4 years 14 21.8
4-13 years 16 25.0
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participants had parkinsonism while one had dyskinesia
and two had both parkinsonism and dyskinesia. Four of
those with SMD were female and three male. Although
a proportionately higher number of women had SMD,
this difference was not statistically significant (Fisher’s
exact p = 0.204). Those with SMD were older, with a
mean (SD) age of 38.3 (12.5) years compared with par-
ticipants without SMD who had a mean age of 28.1
(8.6) years. This difference was statistically significant
(mean difference = 10.2; t = 2.8; p = 0.006). These differ-
ences are reflected in the mean scores for both the SASand AIMS scales, which were relatively higher among
older participants, women and those with more chronic
illness (Table 2). The topography of dyskinetic movements
was primarily orofacial, while the parkinsonian symptoms
were found in the elbow, shoulder and arm regions,
followed by wrist and leg regions.
Nutritional status and substance use behavior
Based on the WHO Expert Committee classification for
Chronic Energy Deficiency in adults, close to half of the
participants (n = 29; 45.3%) were in the underweight
range with a BMI value of less than 18.5. Among those
with low BMI values, 12 (41.4%) had BMI values of less
than 16, which is classified as severely underweight. These
details are presented in Figure 1. Thirty six (56.3%) partici-
pants had either current or past history of substance use
(alcohol, khat, cigarettes or cannabis) and among those
52.4% of those used substances daily.
Exploratory analysis of associated factors
Because of the relatively small sample size and the small
number of cases with SMD, results presented are based
on a bivariate model. Increasing age was associated with
SMD (OR = 1.10; 95% CI = 1.02, 1.20; p = 0.017). An in-
verse association was found between patients’ nutritional
status and the presence of spontaneous movement disor-
ders; therefore increasing body weight (a proxy measure
of dietary health), assessed with BMI, was inversely asso-
ciated with SMD (OR = 0.6; 95% CI = 0.4, 0.8; p =0.01).
The mean score on the Simpson-Angus scale was also
marginally associated with the SANS score (β = .25; 95%
CI = 0.0, 0.06; p = 0.049).
Discussion
This is the first study on this subject in Ethiopia and is
also one of few research reports on this subject from
Africa. We evaluated a total of sixty-four patients with
first contact psychosis who met the DSM-IV-TR criteria
for schizophrenia, schizophreniform, and schizoaffective
psychosis over the period of the study. The principal
finding of this study is the confirmation that movement
disorders occur in persons with schizophrenia spectrum
disorders prior to exposure to antipsychotic medications,
which are often presumed to be the cause of movement
disorders in those with psychotic disorders. In this study
at least one in ten treatment-naïve individuals (10.9%; 7/64)
had spontaneous movement disorders. Most of those with
SMD (6/7) had parkinsonism, while nearly half (3/7) had
dyskinesia either alone or with parkinsonian movement
disorders. The prevalence of spontaneous movement
disorders in our study (10.9%) is consistent with the
prevalence finding of SMDs in previous studies [15],
particularly that of spontaneous parkinsonism [12,17,18],
which lies between 4% and 21%. Rigidity and motor
Table 2 The mean, minimum and maximum Simpson-Angus Rating Scale and the Abnormal Involuntary Movement
Scale scores of participants by demographic and clinical characteristics
Characteristics Simpson-Angus (SAS) score Abnormal Involuntary Movements (AIMS) score
Mean Minimum Maximum Mean Minimum Maximum
Gender Male 0.4 0.0 8.0 0.3 0.0 12.0
Female 1.43 0.0 11.0 0.8 0.0 10.0
Age <24 0.4 0.0 11.0 0.2 0.0 6.0
25-34 0.3 0.0 4.0 0.9 0.0 12.0
≥ 35 1.4 0.0 11.0 0.4 0.0 10.0
BMI ≥ 18.5 0.2 0.0 4.0 0.0 0.0 0.0
<18.5 1.4 0.0 11.0 1.0 0.0 12.0
Duration of illness
(in months)
1-12 0.4 0.0 6.0 0.0 0.0 0.0
13-24 0.2 0.0 2.0 0.0 0.0 0.0
25-48 0.3 0.0 4.0 0.0 0.0 0.0
49-156 2.0 0.0 11.0 1.8 0.0 12.0
Diagnosis Schizophrenia 0.9 0.0 11.0 0.6 0.0 12.0
Schizophreniform disorder 1.2 0.0 6.0 0.0 0.0 0.0
Schizoaffective disorder-bipolar type 0.0 0.0 0.0 0.0 0.0 0.0
Schizoaffective disorder- depressive type 0.0 0.0 0.0 0.0 0.0 0.0
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sonism in our study, consistent with previous studies
[12,18-22] which reported akinetic symptoms, such as
rigidity and bradykinesia, much more frequently than
non-akinetic type movement disorders, such as tremor,
glabelar tap, and salivation in antipsychotic-naïve patient
with parkinsonian movement disorders. Consistent with
previous studies [8,14], the commonly found dyskinestic
symptoms in our study were orofacial movements. Thus,
the findings in our study support the assertion that




Figure 1 Proportion of participants with evidence of malnutrition accinduced state-dependent change, independent of the effect
of antipsychotic medications.
One of the incidental findings of this study is the high
rate of protein energy malnutrition: 45.5% (n = 29) of
participants had BMI value under 18.5, which was signifi-
cantly higher among those with spontaneous movement
disorders, where 6/7 of those with SMD had low BMI.
Alternatively, this could suggest that higher BMI was
protective of SMD. The small number of cases pro-
hibits in-depth speculation about the relevance of this





ording to the BMI-based WHO classification.
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schizophrenia.
The aetiology of schizophrenia and other psychotic
disorders remains largely undefined despite extensive re-
search on possible biological mechanisms. Genetic consti-
tution is important, but environmental factors like an
unhealthy lifestyle with a poor diet may be involved. One
area of focus regarding environmental risk factors has
been around the role of polyunsaturated fatty acids. Low
maternal fish and seafood consumption during pregnancy
has been reported to increase the risk for a low IQ and
suboptimal neuro-developmental outcomes in childhood
[44], factors that in turn are associated with an increased
risk for adult mental disorders like schizophrenia [45]. Re-
search done by Horrobin [46] and Fenton [47] reported
lower levels of polyunsaturated fatty acids (PUFA) in brain
content, red blood cells and skin fibroblasts among pa-
tients with schizophrenia, compared with a healthy popu-
lation. Hedelin et al. [48] also found that a high dietary
intake of fish, omega-3 and omega-6 PUFA, as well as
vitamin D, may have a protective effect against positive
psychotic-like symptoms. However, we did not find studies
reporting association between poor nutrition and SMD
among persons with schizophrenia. This association may
be attributed to specific alterations in subcortical dopa-
mine neuronal activity [18]. Further studies are required
to determine whether poor nutrition is a risk factor for
SMDs.
The other factor significantly associated with SMD
was increasing age. Although some previous studies did
not find such an association [4], increasing age is often
considered an important risk factor for SMD [9,49]. Add-
itionally, there was weak association between negative
symptoms and parkinsonian movement disorder. Ex-
ploratory analysis did not find an association between
duration of illness, gender and SMD, which is consistent
with previous reports [4].
Limitation of the study
The limitations of cross-sectional studies hold true also
for this study. The number of recruited patients was
relatively small and only patients who came to the hospital
were recruited, limiting generalisability. Because of the
small sample size, the analysis for association between
potential risk factors and SMD should be considered
exploratory.
Conclusions
This study supports the argument that involuntary move-
ments (and parkinsonian symptoms) in schizophrenia
may be, at least in part, intrinsic to the pathophysiology of
the illness rather than a side effect of its treatment. Nutri-
tion may simply be a contextual risk factor or represent a
factor linked to the pathophysiology of the illness. Furtherstudies need to confirm these observations and systemat-
ically examine the relationship between SMDs and these
risk factors with a larger sample size and more robust
methodology. Additionally, determining the course of
SMDs and their impact on treatment would also be of
interest.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
MA, TS and AF conceived of the research idea. BM participated in the initial
case screening. MA and AF analysed the data and wrote the initial draft. All
authors contributed to the writing of the final draft and read and approved
the manuscript.
Acknowledgements
The study was conducted by a research grant awarded by Addis Ababa
University to MA. The funding body had no role in developing the study
design; in the collection, analysis, and interpretation of data; in the writing of
the manuscript; and in the decision to submit the manuscript for publication.
We are grateful to Ms. Meghan Davis for editing the English.
Author details
1Department of Psychiatry, Hawassa University, College of Medicine and
Health Sciences, Hawassa, Ethiopia. 2Department of Psychiatry, Addis Ababa
University, College of Health Sciences, School of Medicine, Addis Ababa,
Ethiopia. 3University of Toronto, Ontario Shores Center for Mental Health
Sciences, Toronto, Canada. 4Department of Psychological Medicine, Centre
for Affective Disorders, King’s College London, Institute of Psychiatry, London,
UK.
Received: 23 November 2013 Accepted: 27 September 2014
References
1. Gerlach J, Casey D: Tardive dyskinesia. Acta Psychiatr Scand 1988, 77:369–378.
2. Kane J, Woerner M, Lieberman J: Tardive dyskinesia: rate incidence and risk
factors, in Dyskinesia Research and Treatment. Berlin: Springer; 1985.
3. Kane J, Smith J: Tardive dyskinesia: rate and risk factors. Arch Gen
Psychiatry 1982, 39:473–481.
4. McCreadie R, Strinivasan T, Padmavati R, Thara R: Extrapyramidal
Symptoms in un medicated schizophrenia. J Psychiatr Research 2005,
39:261–266.
5. Pappa S, Dazzan P: Spontaneous movement disorders in antipsychotic-native
patients with first-episode psychoses: a systematic review. Psychol Med 2009,
39:1065–1076.
6. Whitty P, Owoeye O, Waddington J: Neurological Signs and Involuntry
Movements in Schizophrenia: Intrinsic To and Informative on Systems
Pathobiology. Schizophr Bull 2009, 35:415–424.
7. Kraepelin E: Dementia praecox and paraphrenia. E & S Livingstone:
Edinburgh; 1919.
8. Turner T: Rich and mad in Victorian England. Psychol Med 1989, 19:29–44.
9. Liddle P: Tardive dyskinesia in schizophrenia. Br J Psychiatry 2013, 203:6–7.
10. Sarro S, Pomarol-Clotet E, Canales-Rodriguez EJ, Salvador R, Gomar JJ,
Ortiz-Gil J, Landin-Romero R, Vila-Rodriguez F, Blanch J, McKenna PJ: Structural
brain changes associated with tardive dyskinesia in schizophrenia. Br J
Psychiatry 2013, 203:51–57.
11. Caligiuri M, Lohr J: A disturbance in the control of muscle force in
neuroleptic-natve schizophrenic patients. Biol Psychiatry 1994, 35:104–111.
12. Chatterjee A, Chakos M, Koreen A: Prevalence and clinnical correlates of
extrapyra midal signs and spontaneous dyskinesia in never-medicated
schizophrenic patients. Am J Psychiatry 1995, 152:1724–1729.
13. McCreadie R, Thara R, Kamath S: Abnormal movements in never-medicated
Indian patients with schizophreniz. Br J Psychiatry 1996, 168:221–226.
14. Fenton W, Wyatt R, McGlashan T: Risk factors for spontaneous dyskinesia
in schizophrenia. Arch Gen Psychiatry 1994, 51:643–650.
15. Guy W: ECDEU assessment manual for psychopharmacology. Washington, DC:
US Department of Health, Education and Welfare; 1976.
Ayehu et al. BMC Psychiatry 2014, 14:280 Page 7 of 7
http://www.biomedcentral.com/1471-244X/14/28016. Gervin M, Browene S, Lane A: Spontaneous abnormal involuntary
movements in first-episode schizophr-enia and schizophreniform
disorder: baseline rate in a group of patients from an Irish catchment
area. Am J Psychiatry 1998, 155:1202–1206.
17. Puri B, Barnes T, Chapman M, Hutton S, Joyce E: Spontaneous dyskinsesia
in first episode schizophrenia. J Neurol Neurosurg Psychiatry 1999,
66:76–78.
18. Caligiuri M, Lohr J, Jeste D: Parkinsonism in neurolptic-naive schizophrenic
patients. Am J Psychiatry 1993, 150:1343–1348.
19. Fenn D, Moussaoui D, Hoffman W: Movements in never-medicated
schizophrenics. Psychopharmacology 1996, 123:206–210.
20. Kopala L, Good K, Honer W: Extrapyramidddal signs and clinical symptoms
in first-episode schizophrenia: response to low-dose risperidone. J Clin
Psychopharamacology 1997, 17:308–313.
21. Peralta V, Cuesta M, Martinez-Larrea A, Serrano J: Differnetiating primary
from secondary negative symptoms in schizophrenia. Am J Psychiatry
2000, 157:1461–1466.
22. Honer W, Kopala L, Rabinowitz J: Extrapyramidal symptoms and signs in
first-episode, antipsychotic exposed and non-exposed patients with
schizophrenia or related psychotic illness. J Psychopharmacology 2005,
19:277–285.
23. Shawn L, Cassady M, Helene A: Spontaneous Dyskinesia in Subjects with
Schizophrenia Spectrum Personality. Am J Psychiatry 1998, 155:70–7563.
24. Jeroen P, Diederik E, Jim V, Andrr A, Renr S, Peter N: Dyskinesia and
Paarkinsonism in Antipsychotic-Native Patients With Schizophrenia,
First-Degree Relatives and Healthy Controls. A Meta-analysis. Schizophr
Bull 2010, 36:723–731.
25. Fenton W: Prevalence of spontaneous dyskinesia in schizophrenia. J Clin
Psychiatry 2000, 61(Suppl. 4):10–14.
26. Cortese L, Caligiuri M, Malla A, Manchanda R, Takhar J, Haricharan R:
Relationship of neuromotor disturbances to psychosis symptoms in
first-episode neuroleptic-naive schizophrenia patients. Schizophr Res 2005,
75:65–75.
27. Pareek P, Bhojraj T, Montrose D, Rajarethinam R, Sweeney J, Keshava M:
Involuntary movements and their correlates in first-episode psychoses.
Acta Neuropsychiatr 2010, 22(5):262–263.
28. McCreadie R, Latha S, Thara R, Padmavati R, Ayankaran J: Poor memory,
negative symptoms and abnormal movements in never-treated Indian
patients with schizophrenia. Br J Psychiatry 1997, 171:360–363.
29. Sandyk R, Kay S: The relationship of tardive dyskinesia to postive
schizophrenia. Int J Neurosci 1991, 56:107–139.
30. White T, Brown K, Woods J: Tardive dyskinesia and positive symptoms of
schizophrenia. Acta Psychiatri Scand 1991, 83:377–379.
31. Waddington J, Youssef H, Dolphin C, Kinsella A: Cognitive dysfunction,
negative symptoms, and tardive dyskinesia in schizophrenia. Their
association in relation to topography of involuntary movements and
criterion of their abnormality. Arch Gen Psychiatry 1987, 44:907–912.
32. Yarden P, DiScipio W: Abnormal movements and prognosis in
schizophrenia. Am J Psychiatry 1971, 128:317–323.
33. Crown T, Cross A, Johnstone E, Owen F, Owens D, Waddington J: Abnormal
involuntary movements in schizophrenia: are they related to the disease
process or its treatment? Are they associated with changes in dopamine
receptors. J Clin Psychopharamacology 1982, 2:336–340.
34. Rogers D: The motor disorders of severe psychiatric illness: a conflict of
paradigms. Br J Psychiatry 1985, 147:221–232.
35. Fekadu A, Kebede D, Alem A, Fekadu D, Mogga S, Negash A, Medhin G,
Beyero T, Shibre T: Clinical outcome in bipolar disorder in a
community-based follow-up study in Butajira, Ethiopia. Acta
Psychiatr Scand 2006, 114(6):426–434.
36. Kebede D, Alem A, Shibre T, Negash A, Fekadu A, Fekadu D, Deyassa N,
Jacobsson L, Kullgren G: Onset and clinical course of schizophrenia in
Butajira-Ethiopia–a community-based study. Soc Psychiatry Psychiatr
Epidemiol 2003, 38(11):625–631.
37. American Psychiatric Association: Diagnostic and Statistical Manual of Mental
Disorders, 4th Edition, Text revision. Washington, DC: American Psychiatric
Association; 2000.
38. Simpson G, Angus J: A rating scale for extrapyramidal side effects.
Acta Psychiatr Scand 1970, 212:S11–S19.
39. Guy W: ECDEU Assessment Manual for Psychopharmacology. Revised DHEW
Pub. (ADM). National Institute for Mental Health. Psychopharmacology
Resrarch: Rockville, MD; 1976.40. Schooler N, Kamath J: Research diagnoses for tardive dyskinesia(letter).
Arch Gen Psychiatry 1982, 39:486–487.
41. Andreasen N: Scale for the Assessment of Positive Symptoms (SAPS). Unversity
of IOWA: Iowa City; 1984.
42. Andreasen N: Modified Scale for the Assessment of Negative Symptoms
(SANS). Iowa City: University of Iowa; 1984.
43. WHO Expert Committee on Physical Status: The use and interpretation of
anthropometry: report of a WHO expert committee. In WHO Technical
Report Series 854. Geneva: World Health Organization; 1995.
44. Hibbeln J, Davis J, Steer C: Maternal seafood consumption in pregnancy
and neurodevelopmental outcomes in childhood (ALSPAC study): an
observational cohort study. Lancet 2007, 369(9561):578–585.
45. Koenen K, Moffitt T, Roberts A: Childhood IQ and adult mental disorders:
a test of the cognitive reserve hypothesis. Am J Psychiatry 2009,
166(1):50–57.
46. Horrobin D: The membrane phospholipid hypothesis as a biochemical
basis for the neurodevelopmental concept of schizophrenia. Schizophr
Res 1998, 30(3):193–208.
47. Fenton W, Hibbeln J, Knable M: Essential fatty acids, lipid membrance
abnormalities, and the diagnosis and treatment of schizophrenia.
Biol Psychiatry 2000, 47(1):8–21.
48. Hedelin M, Luf M: Dietary intake of fish, omega-3, omega-6 polyunsaturated
fatty acids and vitamin D and the prevalence of psychotic-like symptoms
in a cohort of 33000 women from the general populaation. BMC Psychiatry
2010, 10:38.
49. Merrill RM, Lyon JL, Matiaco PM: Tardive and spontaneous dyskinesia
incidence in the general population. BMC Psychiatry 2013, 13:152.
doi:10.1186/s12888-014-0280-1
Cite this article as: Ayehu et al.: Movement disorders in neuroleptic-
naïve patients with schizophrenia spectrum disorders. BMC Psychiatry
2014 14:280.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
